Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA)-1 mg

Description

Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Cancer-programmed cell death–C28H39F3N8O9—-[1]Shen ZH, et al. Targeting of the leukemia microenvironment by c(RGDfV) overcomes the resistance to chemotherapy in acute myeloid leukemia in biomimetic polystyrene scaffolds. Oncol Lett. 2016 Nov;12(5):3278-3284.–199807-33-5–688.65–99.70–O=C([C@@H](NC(CNC([C@H](CCCNC(N)=N)NC([C@H](C(C)C)NC1=O)=O)=O)=O)CC(O)=O)N[C@@H]1CC2=CC=CC=C2.FC(C(O)=O)(F)F–Cancer–10 mM in DMSO–Apoptosis;Integrin—-Apoptosis;Cytoskeleton–Peptides